We’re passionate about improving the quality of life for people with solid cancer
Cartherics aims for a better quality of life for cancer patients with its CAR-iNK technologies aimed at enabling better, lower cost and more accessible treatment for patients.
Immunotherapy in oncology is globally recognized as a revolutionary therapeutic modality with enormous potential.
Join a team that’s helping drive this new field.
People & Careers News
Congratulations Dr Mathew Tiedemann!
July 16, 2025
Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive...
Read More
The critical importance of navigating the complexity of healthcare markets
July 11, 2025
In the competitive biotech landscape, groundbreaking science alone isn't enough. As highlighted in a recent article by Dynamic Business, Cartherics'...
Read More
Cartherics COO Dr Ian Nisbet on the promise of CAR-NK cells for cancer and endometriosis at BIO 2025
June 18, 2025
In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative...
Read More
Bridging Borders: The Strategic Value of U.S.-Based Directors for Australian Biotech Companies
May 19, 2025
Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications. As global demand for biotechnology products and services...
Read More
World Ovarian Cancer Day – Insights from Board Advisor, Heather Hawkins
May 8, 2025
Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins - ovarian cancer...
Read More
Cartherics appoints new Board Chair and Non-Executive Director
April 16, 2025
Cartherics appoints Prof. Bryan Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director Melbourne, Australia, 16 April...
Read More
Cartherics strengthens scientific and manufacturing team
March 20, 2025
Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams,...
Read More
Message from the CEO
December 16, 2024
As we reflect on 2024, it's clear that this year has been a defining chapter in Cartherics' 10-year history. We've...
Read More
Cartherics’ CEO named ScholarGPS highly ranked scholar for outstanding scholarly contributions
September 20, 2024
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar...
Read More
The first baby from a frozen embryo turns 40!
May 2, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of...
Read More
Cartherics appoints new Chief Scientific Officer
October 17, 2023
Melbourne, Australia, 17 October 2023 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
Bio Connections Australia 2023 promotes science commercialisation
July 31, 2023
Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world...
Read More
Australia – China Science and Innovation Forum fosters collaboration and commercialisation
June 28, 2023
The 2023 Australia-China Science and Innovation Forum focused on leading-edge Australian and Chinese biomedical research collaborations and commercialisation. The forum...
Read More
Global IP takes centre stage at the 21st Advanced Summit on Life Sciences Patents
May 30, 2023
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in...
Read More
Cartherics congratulates Rasa Islam on PhD success
May 16, 2023
Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature. Rasa’s research thesis, titled, Re-engineering the...
Read More
